AIMS: Hawthorn's efficacy when added to contemporary evidence-based @entity712 therapy is unknown. We aimed to determine whether hawthorn increases submaximal exercise capacity when added to standard medical therapy. METHODS AND RESULTS: We performed a randomized, double-blind, placebo-controlled trial in 120 ambulatory @entity1 aged > or = 18 years with New York Heart Association (NYHA) class II-III chronic @entity712 . All @entity1 received conventional medical therapy, as tolerated, and were randomized to either hawthorn 450 mg twice daily or placebo for 6 months. The primary outcome was change in 6 min walk distance at 6 months. Secondary outcomes included quality of life (QOL) measures, peak @entity26 consumption, and anaerobic threshold during maximal treadmill exercise testing, NYHA classification, left ventricular ejection fraction (LVEF), neurohormones, and measures of oxidative stress and @entity32 . There were no significant differences between groups in the change in 6 min walk distance (P = 0.61), or on measures of QOL, functional capacity, neurohormones, oxidative stress, or @entity32 . A modest difference in LVEF favoured hawthorn (P = 0.04). There were significantly more adverse events reported in the hawthorn group (P = 0.02), although most were non-cardiac. CONCLUSION: Hawthorn provides no symptomatic or functional benefit when given with standard medical therapy to @entity1 with @entity712 . This trial is registered in ClinicalTrials.gov ID: NCT00343902.

Hawthorn Extract Randomized Blinded XXXX (HERB CHF) trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']
@entity712 :: (MESH:D006333,Disease) :: ['Chronic Heart Failure']
